Investing in vaccines is a ‘no-brainer’

Adam Tooze writes for the FT Weekend, reinforcing the ‘unbeatable’ cost-benefit ratio of investing in vaccines now to better prepare for a future Disease X threat.

on.ft.com/3xdlUck

Check out February's Updates & Insights ✨

From future-proofing vaccine production in Africa to advancing diagnostics for Nipah virus and Lassa fever, plus plenty more, this month's newsletter covers it all.

linkedin.com/pulse/future-p…

What exactly is Disease X?

With the concept of #DiseaseX at the heart of efforts to be better prepared for future pandemics, CEPI looks at what people most want to find out about this unknown pathogen.

Check out our explainer blog to learn more ⬇️
cepi.net/news_cepi/dise…

Could a chrysalis-based ‘living bioreactor’ prove an innovative method for speeding up human vaccine production? Scientists in Spain are set to find out. bit.ly/4b35EKn

Check out CEPI’s latest funding partnership to learn more ⬇️

Congratulations and a warm welcome to Dr Senator Dr Sania Nishtar, the incoming CEO of @Gavi. I look forward to continuing @CEPIvaccine’s collaboration with @Gavi, under Dr Nishtar’s leadership, as we continue to drive forward our shared mission of ensuring equitable access to vaccines

Today, at a press conference in Kigali 🇷🇼, CEPI announced a new partnership with Rwanda-owned Akagera Medicines.

The partnership will advance the development of Akagera Medicines' innovative lipid nanoparticles and modified mRNA technology. Learn more➡️bit.ly/3NuKtqI

H.E. Paul Kagame, President of the Republic of Rwanda, speaking at the inauguration of the BioNTech SE #BioNTainer facility in the #Kigali Innovation City Industrial Park:

'This facility is designed to be among the most advanced in the world. Most of the staff, including the

It was an honor to meet with British Ambassador to Japan, Julia Longbottom, to discuss pandemic prevention, preparedness, and response; the #100DaysMission ; and CEPI continued efforts to accelerate innovation of, and enable equitable access, to vaccines. Foreign, Commonwealth & Development Office

CEPI CEO Richard Hatchett was honoured to meet 古屋 範子 and Komeito Party colleagues in Tokyo this week 🇯🇵 They discussed strengthening cooperation between CEPI and Japan’s life sciences institutions and industry and Japan’s leadership in global health during its G7 Presidency.

#ÖzlemTüreci , on the history of #mRNA vaccines and BioNTech SE -- @CEPIVaccines strategic partner. Very honored to share the podium with her, John-Arne Røttingen and Agnete B. Fredriksen.

The Arenavirus family. It includes some of the most lethal haemorrhagic fevers known. All of its prime suspects can cause life-threatening illness and death.
tinyurl.com/yc34e4ws #TheViralMostWanted

Yesterday I had the great pleasure to attend a meeting with the Norwegian Alumni Clubs of Stanford, MIT and Harvard Universities to discuss how the world can strengthen health security.

It was inspiring to discuss this important topic with John-Arne Røttingen, Tore Godal and Line Vold.

Tune in to watch our CEO, Richard Hatchett, tomorrow as he joins world leading experts at Massachusetts Consortium on Pathogen Readiness to explore how a global framework for pandemic preparedness can be developed and how your organisation can participate in it.

📺Tune in LIVE from 0900 EDT youtube.com/watch?v=jLdZrb…

HERA & CEPI facilitated a Roundtable on the power of collaboration to address medical countermeasures R&D for epi & pandemic threats.

Collaboration could help drive breakthroughs in science & technology, progress in vaccine & therapeutics development.

👉 europa.eu/!44BCYQ

How can AI be used to help anticipate future viral variants that could avoid immune detection?
bit.ly/3tH4gMB

CEPI is pleased to welcome Doherty Institute as they become the latest member to join CEPI’s Centralised Laboratory Network, the largest global group dedicated to the standardised testing of epidemic and pandemic vaccines.

cepi.net/news_cepi/aust…

Scientists racing to stop the next pandemic take inspiration from pioneering Covid trials.

CEPI $3.5 billion five-year “100 Days Mission”, to prepare the ground for global vaccine testing, is well underway.

Lilia Sebouai has the latest.

telegraph.co.uk/global-health/…